Figure 4.

Knockdown of PART‐1 suppressed proliferation and cell cycle of NSCLC cells. A, Transfection efficiency of PART1 shRNAs (PART1‐sh1/sh2) in A549 and SK‐MES‐1 cells. **, ***P < .01, P < .001. B, Detection of PART1‐sh1/sh2 on the cell viability by MTT assay. ***P < .001. C, Detection of PART1‐sh1/sh2 on the cell proliferation by EdU staining. D, Detection of PART1‐sh1/sh2 on the cell cycle by flow cytometry. EdU, 5‐Ethynyl‐2’‐deoxyuridine; MTT, 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐tetrazolium bromide; NSCLC, non‐small cell lung cancer; PART1, prostate androgen‐regulated transcript 1